A public health agency should clarify whether Pfizer’s COVID-19 vaccine showed efficacy in those with a previous infection, Rep. Thomas Massie (R-Ky.) said. The Centers for Disease Control and Prevention (CDC) advisory committee last month published recommendations for use of the vaccine. It said that a clinical trial showed the vaccine had consistently high efficacy for people with or without a previous infection. Massie alleged the interpretation wasn’t true. He called the CDC and spoke with multiple officials, with several appearing to admit the wording needed to be updated. “As you note correctly, there is not sufficient analysis to show that in the subset of only the people with prior infection, there’s efficacy,” Anne Schuchat, the CDC’s principal deputy director, said in one of the calls. The recommendations were corrected with different wording on Jan. 29. The report now states: “Consistent high efficacy (≥92 percent) was observed across age, sex, …